Company intelligence / Profile preview

Reactive Biosciences

Durham, North Carolina, United Statesreactivebio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Reactive Biosciences leverages a proprietary boron-centric drug discovery platform to develop novel small molecule therapeutics targeting previously undruggable disease areas. The company is in the preclinical stage, with no reported clinical results or late-stage assets as of 2024[1][2].

Therapeutic areas: Other
Modalities: Small molecules (boron-based compounds)Structure-based drug design enabled by computational chemistry[1][2][5]
Industry: Biotech

Partnerships

No major pharmaceutical partnerships publicly announced, but the company is actively seeking collaborations for its platform technology[5].

Beyond the preview

Go deeper on Reactive Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reactive Biosciences.

Explore the full profile